Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
70
VNDA Quote, Financials, Valuation and Earnings
Last price:
$6.92
Seasonality move
:
-3.34%
Day range:
$6.75 - $6.94
52-week range:
$3.81 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.89x
P/B ratio:
0.87x
Volume:
1.5M
Avg. volume:
1.3M
1-year change:
46.15%
Market cap:
$404.2M
Revenue:
$198.8M
EPS (TTM):
-$1.43
Analysts' Opinion
-
Consensus RatingVanda Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.75, Vanda Pharmaceuticals, Inc. has an estimated upside of 71.78% from its current price of $6.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $6.84.
Fair Value
-
According to the consensus of 4 analysts, Vanda Pharmaceuticals, Inc. has 71.78% upside to fair value with a price target of $11.75 per share.
VNDA vs. S&P 500
-
Over the past 5 trading days, Vanda Pharmaceuticals, Inc. has overperformed the S&P 500 by 0.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Vanda Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vanda Pharmaceuticals, Inc. has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Vanda Pharmaceuticals, Inc. reported revenues of $56.3M.
Earnings Growth
-
Vanda Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Vanda Pharmaceuticals, Inc. reported earnings per share of -$0.38.
Enterprise value:
121.4M
EV / Invested capital:
0.25x
Price / LTM sales:
1.89x
EV / EBIT:
--
EV / Revenue:
0.57x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-1.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$193.3M
Return On Assets:
-13.33%
Net Income Margin (TTM):
-39.7%
Return On Equity:
-16.55%
Return On Invested Capital:
-16.2%
Operating Margin:
-55.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $211.9M | $190.9M | $212.1M | $47.7M | $56.3M | |
| Gross Profit | $192.8M | $172.2M | $193.3M | $43.3M | $51.6M | |
| Operating Income | -$229K | -$37.5M | -$121.1M | -$11M | -$31.3M | |
| EBITDA | $2.3M | -$30.2M | -$113.1M | -$9M | -$29.2M | |
| Diluted EPS | $0.21 | -$0.28 | -$1.43 | -$0.09 | -$0.38 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $461.8M | $507.1M | $536.6M | $432.4M | $367.5M | |
| Total Assets | $579.8M | $621.8M | $641.6M | $645.1M | $601.1M | |
| Current Liabilities | $72M | $92.6M | $84.8M | $89.1M | $117.9M | |
| Total Liabilities | $86.4M | $106.1M | $98.5M | $103.9M | $135.1M | |
| Total Equity | $493.3M | $515.7M | $543.1M | $541.2M | $466M | |
| Total Debt | $12.8M | $8.9M | $7.5M | $5.5M | $8.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $25.9M | -$17.7M | -$81.8M | -$14.6M | -$31.6M | |
| Cash From Investing | $107.2M | -$65.2M | $54M | $12.1M | $21.4M | |
| Cash From Financing | $605K | -- | -$2.4M | -- | -$517K | |
| Free Cash Flow | $25.6M | -$18.2M | -$83M | -$14.7M | -$31.8M | |
VNDA
Sector
Market Cap
$404.2M
$28.1M
Price % of 52-Week High
95%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-0.17%
-1.49%
1-Year Price Total Return
46.15%
-17.13%
Beta (5-Year)
0.687
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.70
200-day SMA
Buy
Level
$4.78
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$6.03
Relative Strength Index (RSI14)
Buy
Level
66.35
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-17.8218
50-day SMA
Buy
Level
$5.35
MACD (12, 26)
Buy
Level
1.69
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7707)
Buy
CA Score
(Annual)
Level (0.8902)
Buy
Beneish M-Score
(Annual)
Level (-2.2972)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.1125)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Stock Forecast FAQ
In the current month, VNDA has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VNDA average analyst price target in the past 3 months is $11.75.
-
Where Will Vanda Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vanda Pharmaceuticals, Inc. share price will rise to $11.75 per share over the next 12 months.
-
What Do Analysts Say About Vanda Pharmaceuticals, Inc.?
Analysts are divided on their view about Vanda Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vanda Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Vanda Pharmaceuticals, Inc.'s Price Target?
The price target for Vanda Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $11.75 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VNDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vanda Pharmaceuticals, Inc. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VNDA?
You can purchase shares of Vanda Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vanda Pharmaceuticals, Inc. shares.
-
What Is The Vanda Pharmaceuticals, Inc. Share Price Today?
Vanda Pharmaceuticals, Inc. was last trading at $6.92 per share. This represents the most recent stock quote for Vanda Pharmaceuticals, Inc.. Yesterday, Vanda Pharmaceuticals, Inc. closed at $6.84 per share.
-
How To Buy Vanda Pharmaceuticals, Inc. Stock Online?
In order to purchase Vanda Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VNDA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VNDA
Sector
P/E ratio
--
23.89x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.87x
1.81x
Price / LTM sales
1.89x
1.59x
Growth Metrics
VNDA
Sector
Revenue growth
18.06%
4.62%
Earnings growth
-318.16%
11.06%
Revenue (5-year growth)
-2.64%
6.5%
Earnings forecast
--
-$0.21
Profitability
VNDA
Sector
Profitability FY 2024
$180.2M
$3.6M
Return on invested capital
-16.2%
-31.84%
Return on assets
-13.33%
-27.96%
Return on equity
-16.55%
-37.63%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
11
Estimated Next Earnings Date
Jan
28
Balance Sheet
VNDA
Sector
Total cash
$293.8M
$26.4M
Short term investments
$272.3M
$25.7M
Total assets
$656.2M
$76.9M
Long term debt
$8.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
